Intertek Acquires Melbourn - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Intertek Acquires Melbourn
The acquisition of Melbourn extends Intertek's offering to include formulation, product development and characterisation of orally inhaled and intranasal products amongst others.


Intertek has acquired Melbourn Scientific Ltd, a provider of analysis and development services for the pharmaceutical, biopharmaceutical, biotechnology and healthcare industries, based in Royston, near Cambridge, UK.

Melbourn offers a range of services to support the global pharmaceutical and healthcare industry including formulation and product development, analytical method development and validation, stability studies and QC release testing. In addition to services for conventionally delivered medicines, the company has expertise in characterization of orally inhaled and intranasal products (OINDP) and transdermal devices.

Patient-friendly drug-delivery methods have been gaining popularity as a means to achieve optimum therapeutic efficacy and efficiency as well as enhanced patient outcomes. Melbourn’s formulation services include reformulation of existing products to improve efficacy or extend patent life and to widen the market potential for a given product. As an example, reformulating an injection into an oral inhalation product is a key strategy of many global pharmaceutical majors to achieve increased market share by improving bioavailability and drug use uptake within a patient population (i.e., by improving delivery at the target) whilst reducing patient trauma.

Melbourn’s 20,000-square-feet facility complies with GMP standards and is regularly inspected by the UK Medicines and Health Regulatory Authority (MHRA) and the FDA.

Dr. Andrew Swift, vice-president of Intertek Chemicals and Pharmaceuticals, said in a press statement that combining the company’s capabilities for measuring device and drug interaction with Melbourn’s expertise in OINDP drug characterization would provide a unique offering to support drug development.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here